Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

3.320 +0.120 (+3.75%)
Streaming Delayed Price Updated: 12:11 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 148,862
Open 3.230
Bid (Size) 3.310 (2)
Ask (Size) 3.330 (3)
Prev. Close 3.200
Today's Range 3.218 - 3.420
52wk Range 1.730 - 7.380
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026 
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire

Performance

YTD
-26.1%
-26.1%
1 Month
+74.7%
+74.7%
3 Month
-29.5%
-29.5%
6 Month
-46.4%
-46.4%
1 Year
-25.2%
-25.2%

More News

Read More
The market is filled with gapping stocks in Monday's session.
Via Chartmill
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
From Sagimet Biosciences Inc.
Via GlobeNewswire
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Via Investor's Business Daily
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
From Sagimet Biosciences Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Sagimet Biosciences Inc. - Series A Common Stock publicly traded?
Yes, Sagimet Biosciences Inc. - Series A Common Stock is publicly traded.
What exchange does Sagimet Biosciences Inc. - Series A Common Stock trade on?
Sagimet Biosciences Inc. - Series A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock?
The ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock is SGMT on the Nasdaq Stock Market
What is the current price of Sagimet Biosciences Inc. - Series A Common Stock?
The current price of Sagimet Biosciences Inc. - Series A Common Stock is 3.320
When was Sagimet Biosciences Inc. - Series A Common Stock last traded?
The last trade of Sagimet Biosciences Inc. - Series A Common Stock was at 05/09/25 12:11 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.